Long-term bladeless LASIK outcomes with the FS200 Femtosecond and EX500 Excimer Laser workstation: the Refractive Suite
A John Kanellopoulos,1,2 George Asimellis1
1Laservision.gr Institute, Athens, Greece; 2NYU Medical School, NY, USA
Purpose: The evaluation of the safety, efficacy, and long-term stability of LASIK procedures utilizing novel platform comprising a femtosecond and excimer laser and multiple networked diagnostics.
Setting: Private clinical ophthalmology practice.
Patients and methods: In consecutive cases of myopic LASIK procedure with a novel refractive platform (FS200 Femtosecond and EX500 Excimer Laser), 190 eyes (from 109 different patients) were evaluated pre- and postoperatively for the following parameters: refractive error, best corrected distance visual acuity, uncorrected distance visual acuity, topography (Placido-disc based) and tomography (Scheimpflug-image based), wavefront analysis, pupillometry, and contrast sensitivity. Follow-up visits were conducted for at least 12-months.
Results: The change from pre- to postoperative mean refractive error was from −5.29 ± 2.39 diopters (D) (range −8.0 to −0.50 D) to −0.27 ± 0.09 D at the 3 month visit, −0.27 ± 0.10 D at the 6 month visit, and −0.39 ± 0.08 D at the 1-year visit. The change from pre- to postoperative refractive astigmatism was −1.07 ± 0.91 D (range −4.25 to 0 D) to −0.14 ± 0.04 D at 3 months, −0.15 ± 0.04 at 6 months, and −0.16 ± 0.04 at the one-year visit. The proportion of the eyes with postoperative astigmatism within 0.5 D ranged between 95.6% and 99%. The proportion of eyes achieving uncorrected distance visual acuity of 1.0 (decimal) was 93.0%.
Conclusion: The myopic LASIK clinical results with the FS200 Femtosecond Laser and EX500 Excimer Laser showed outstanding efficacy, great safety, and long-term stability.
Keywords: bladeless LASIK flap, femtosecond laser, myopic correction, long-term stability, regression, astigmatism correction, post-LASIK refraction
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.